Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Chronic hepatitis B and NASH: Is "fat" all bad?

Chronic hepatitis B and NASH: Is "fat" all bad? Hepatology (Baltimore, Md.) Li, J. n., Cheung, R. C., Nguyen, M. H. 2019

Abstract

We read with interest the recent paper by Choi et al(1) on the impact of biopsy-proven NASH on CHB outcomes. The study concluded that compared to patients with CHB alone, CHB patients with concomitant NASH were more likely to have advanced fibrosis (F3/4) and shorter time to liver complications, and that superimposed NASH predicted poorer outcomes in those with advanced fibrosis. However, prior studies have also suggested that CHB patients with co-existing hepatic steatosis may not be at higher risk for disease progression; and in fact, more favorable long-term outcomes were even reported by some.

View details for DOI 10.1002/hep.30983

View details for PubMedID 31595532